Urology Medical News about angiogenic therapy, renal cell carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention
Urologic Oncology: Seminars and Original Investigations, 07/24/09

Staehler M et al. - In a study to test whether complete remission (CR)can be achieved with angiogenic therapy in metastatic renal cell carcinoma (mRCC) including surgical intervention, it appears that long-term confirmed CR was attained in mRCC through anti-angiogenic therapy alone or in combination with surgery. Combining surgery and anti-angiogenic therapy based on sorafenib and sunitinib could render pts free of disease even after repeated cycles of systemic treatment.

Methods

194 consecutive pts from an institutional database that were treated for mRCC with either sorafenib or sunitinib between 05/2006 and 12/2007 were assessed.
Restaging with repeated high-resolution computed tomography (CT) of thorax and abdomen was performed in an 8- to 10-wk interval.
5 pts who achieved CR in repeated CT under therapy are included in this analysis.

Results

Of the pts in whom CR was achieved, 2 were female and 3 were male.
Median age was 63.2 yrs; all pts had clear cell histology.
In 3 of 5 pts, CR was achieved by surgery after partial remission, and in 2 pts it was achieved by sole medical therapy.
All pts remained in CR until now with a median duration of CR of 24 mos.
1 pt still is on therapy, while 4 pts do not receive any systemic treatment.

<< Previous
Dietary vitamins E and C and prostate cancer risk

Next >>
Prophylactic use of isepamicin and levofloxacin for transrectal...